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Abstract
The interplay between dopamine and a-synuclein (AS) plays a central role in Parkinson’s disease (PD). PD results primarily
from a severe and selective devastation of dopaminergic neurons in substantia nigra pars compacta. The neuropathological
hallmark of the disease is the presence of intraneuronal proteinaceous inclusions known as Lewy bodies within the surviving
neurons, enriched in filamentous AS. In vitro, dopamine inhibits AS fibril formation, but the molecular determinants of this
inhibition remain obscure. Here we use molecular dynamic (MD) simulations to investigate the binding of dopamine and
several of its derivatives onto conformers representative of an NMR ensemble of AS structures in aqueous solution. Within
the limitations inherent to MD simulations of unstructured proteins, our calculations suggest that the ligands bind to the
125YEMPS129 region, consistent with experimental findings. The ligands are further stabilized by long-range electrostatic
interactions with glutamate 83 (E83) in the NAC region. These results suggest that by forming these interactions with AS,
dopamine may affect AS aggregation and fibrillization properties. To test this hypothesis, we investigated in vitro the effects
of dopamine on the aggregation of mutants designed to alter or abolish these interactions. We found that point mutations
in the 125YEMPS129 region do not affect AS aggregation, which is consistent with the fact that dopamine interacts non-
specifically with this region. In contrast, and consistent with our modeling studies, the replacement of glutamate by alanine
at position 83 (E83A) abolishes the ability of dopamine to inhibit AS fibrillization.
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Introduction
Parkinson’s disease (PD) is the second most common progressive
neurodegenerative disorder, affecting 1–2% of the population over
65 [1,2]. The clinical symptoms of PD include muscle rigidity,
resting tremor, bradykinesia and gait disturbance with disequilib-
rium. Neuropathologically, PD is characterized by a selective
degeneration of specific subsets of mesencephalic dopaminergic
cells in the brain and the formation of cytoplasmic aggregates
called Lewy bodies (LBs). The major proteinaceous building block
of LBs are insoluble fibrils made up of the a-synuclein (AS) protein
[3], suggesting that the aggregation of this protein may play a
central role in the development and/or progression of the disease.
This idea is supported by evidence from genetics, animal
modeling, cell culture and biophysical studies: 1) increased
production (gene duplication and triplication [4,5]) and/or
missense mutations (A53T A30P, and E46K) [6–8]) in the gene
encoding for AS are linked to autosomal dominant inherited forms
of familial PD; 2) several lines of transgenic mice and flies that
overexpress wild-type and disease-associated variants of AS show
age-dependent formation of AS-containing inclusions, loss of
dopaminergic cells and motor abnormalities [9,10]; 3) overex-
pression of AS causes cell death in cultured dopaminergic neurons
and in differentiated neuroblastoma cells [11]; 4) all PD associated
mutations have been shown to accelerate and enhance the
oligomerization and fibrillogenesis of AS in vitro [12,13]; 5) AS
toxicity and fibrillization is influenced by factors that may be
relevant to PD, including post-translational modifications, oxida-
tive stress and interaction with toxins and metals [14–18]. Other
neurodegenerative diseases are characterized by the accumulation
of fibrillar AS, including a LB variant of Alzheimer’s disease,
dementia with LB, multiple system atrophy and related diseases,
which collectively are referred as a-synucleinopathies [19].
The AS sequence (140 amino acids) can be divided into three
different regions: (i) the positively charged N-terminal region (amino
acids 1–60) comprising the seven imperfect 11 amino acids repeats
containing the consensus sequence KTKEGV; (ii) the non-b-
amyloid component (NAC) (amino acids 61–95); (iii) the negatively
charged C-terminal region (amino acids 96–140), which contains
several sites of post-translational modifications and metal binding.
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Structural information derived from NMR studies for the
monomeric structure of AS is increasingly used to study and model
AS aggregation and its interaction with other proteins [20–22]. In
aqueous solution, AS exists as a highly heterogeneous ensemble of
conformations. NMR studies based on paramagnetic relaxation
enhancement (PRE) effects generated an ensemble of about 4,000
structures characterized by transient long-range interactions [22].
Upon binding to SDS micelles and negatively charged synthetic
vesicles [23], AS adopts a partially a-helical conformation: two a-
helices (amino acids 1–38 and 44–94) are formed in a non-polar
environment, whilst the remainder of the protein is disordered, as
shown by NMR spectroscopy [23]. The monomer is prone to
aggregation into amyloid-like structures, particularly at high
concentrations or upon exposure to various chemical and physical
factors (e.g. shaking). The AS fibrillization proceeds through a
series of b-sheet-rich aggregation intermediates, including early
spherical protofibrils, pore-like and chain-like aggregates, which
disappear once amyloid fibrils are formed [12,24]. Although
mounting evidence points towards a prefibrillar species as the toxic
entity, the identity of the exact toxic species and its mode of action
remain unknown and are the subjects of intense study and debate
[24–26].
The proposed biological functions for AS include the regulation
of lipid metabolism [27–29], vesicle-mediated transport [28],
trafficking within the endoplasmic reticulum/Golgi network
[30,31] and chaperone activity [32,33]. In addition, AS has also
been shown to regulate dopamine metabolism at multiple levels
including its synthesis, uptake and release [29,34–36]. Several in
vitro and cell culture studies suggest that direct interactions
between dopamine and AS play a central role in the pathogenesis
of PD. Chatechol derivatives including dopamine have been
shown to inhibit AS fibrillogenesis causing accumulation of
oligomeric species in vitro [37,38] and in vivo [39,40]. These studies
suggest that the oxidation of dopamine may play a key role in
modulating AS aggregation and toxicity and may be linked to the
selective vulnerability of dopaminergic neurons in PD [41].
Therefore, investigating the structural determinants of dopamine
binding may shed light on the mechanisms by which this molecule
modulates AS fibrillization and toxicity, thus providing new clues
for therapeutics intervention in PD and related diseases.
Here, we perform a series of molecular dynamic (MD)
simulations and biophysical studies in order to identify both the
residues and the nature of the interactions that mediate the
binding of dopamine to structures of AS. Our modeling studies are
based on structures of AS obtained by NMR spectroscopy [22]
and MD simulations. Our calculations suggest that dopamine
(DOP) as well as several products derived from its oxidation
(Figure 1) [42,43], bind to the C-terminal region comprising the
residues 125YEMPS129, which is consistent with previous exper-
imental findings [38,40]. Such interactions are mostly hydropho-
bic in nature. In addition, our calculations indicate that AS-DOP
interactions are further stabilized by long-range electrostatic
interactions with glutamate 83 (E83) in the NAC region. We
confirm these findings by in vitro fibrillization studies on AS
mutants designed to either alter and/or abolish the specific
interactions identified by our modeling studies.
Materials and Methods
Computational Chemistry
The initial models of ASNdopamine adducts are based on
selected AS conformations from NMR [22] and MD calculations,
performed by us here.
Adducts based on NMR. We considered the 3,062
conformers of ref. [22] that exhibit five or less amino acids (not
Gly) in the forbidden regions of the Ramachandran plot, as
defined by the ‘‘what_check’’ algorithm [44]. We used a method
that clusters conformational ensembles into suitable similarity
classes, for which 87 representative conformations were identified
[45]. The method uses the root mean square distance (RMSD)
distribution of the Ca carbons for each distinct pair of
conformations. In our case, such distribution has a Gaussian-like
shape, with its maximum at 21 A˚ (Figure S1a). A ‘‘proximity
score’’ is then defined as the number of conformations within a
RMSD cutoff, which is self-consistently determined during the
calculations, from a particular conformer. The conformer with the
largest proximity score and the all conformations within the cutoff
are then selected and the remaining conformations proceed to the
next clustering step. The procedure is repeated until all the
conformers are selected. The conformer with the highest
proximity score within its cluster is considered the representative
of the cluster itself. An optimal cutoff provides few clusters with
high proximity score. Based on this criterion, we used here a cutoff
of 19 A˚. With this choice, the first 6 clusters cover about 75% of
the conformations (see the supplementary information: ‘‘Cluster
analysis S1’’).
The seven ligands shown in Figure 1 were docked onto these six
representative conformations of AS using AUTODOCK 3.0 [46].
This procedure was used only to generate initial models for
subsequent analysis (in several cases, the ligands experience a very
high mobility during the dynamics; see results). The parameters for
the molecules were calculated using the AUTODOCK standard
parameterization procedure [46]. The Lamarckian Genetic
Algorithm [46] was applied as a search method for the different
Figure 1. Dopamine docked onto AS: chemical formulas of the proposed dopamine forms binding to AS [42].
doi:10.1371/journal.pone.0003394.g001
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docking results. Therefore, 42 complexes were considered. The
potential grid map for each atom type was calculated using a cubic
box of 252 grid points in each direction, with a distance of 0.5 A˚
between grid points. For each complex, 100 docking runs were
performed resulting in a total of 4,200 calculations. The ligand’s
location was then identified using a cutoff distance criterion of 5 A˚
between the Ca carbons of each amino acid and the center of mass
of each ligand. The most probable region of interaction for each
complex was identified using a cluster analysis based on the
RMSD distance among the ligands on each run (RMSD cutoff of
2 A˚).
Crosschecking of the results. To crosscheck the robustness
of our results, we carried out two additional calculations.
1- A different clustering analysis was performed based on a
smaller number of starting structures (1,000 randomly
selected out from the above ensemble of NMR structures)
using a different clustering algorithm. The algorithm was
taken from Kelley et al. [47]. It is a hierarchical clustering
methodology that uses the average linkage algorithm with an
automatic determination of the cutoff distance. The algo-
rithm identified 80 clusters or families, with an average
spread cutoff of 17.6 ,. Only the first 18 representative
conformations (for the first 18 clusters) were taken into
account for the analysis as they covered approximately the
50% of the total number of conformations.
2- To provide an additional structure which is largely different
from those obtained by NMR, we used molecular dynamics
(MD) simulations. This theoretical model was used to test the
hypothesis that even the use of a different initial conforma-
tion would yield the same result as that obtained using the
NMR structures, namely that dopamine binds to AS in a
region close to the C-terminal region. Our procedure was as
follows: (a) building of an ensemble of AS structural models
by performing some preliminary MD simulations in implicit
solvent; (b) selection of the AS structure with the largest
RMSD value relative to the 6 representative NMR
structures; (c) relaxation of this conformer of AS in aqueous
solution by MD simulations; (d) construction of the adducts
with the ligands in Figure 1 by molecular docking; (e)
relaxation of the adducts in aqueous solution by MD
simulations (described in the following section).
(a) Three 10 ns MD simulations in implicit solvent were
performed starting from an extended conformation of the
protein (Figure S1b). The simulations differed only in the
velocities of the atoms, obtained by three different Maxwell-
Boltzmann distributions. The extended conformations were
generated by assigning to the w and y backbone angles a
value of 180u for all residues except proline (for which
w=260u and y= 180u were used). The side chain geometry
of the amino acids was assigned according to the AMBER8’s
residues templates [48]. The MD simulations in implicit
solvent were carried out using the Hawkins, Cramer,
Truhlar pairwise generalized Born model [49,50], as
implemented in the AMBER8 program [48], using the
AMBER99 [51] force field. The time-step was set to 1 fs.
Dielectric constants values of 1.0 and 78.5 were used for the
protein and solvent respectively. No ionic strength was
assumed. A cutoff distance of 20 A˚ was used for the
electrostatic and van der Waals interactions. The simulations
were performed at T = 300 K by coupling the systems with a
Langevin thermostat [52], with a collision frequency of
2 ps21. Five hundred AS structures were collected at every
0.02 ns for each of the three MD simulations.
(b) These structures were subjected to the cluster analysis as
described above [45]. Twenty representative structures,
which represent 75% of the structure ensemble, were
selected. Among these, the structure of the protein with
the largest RMSD value relative to the 6 representative
NMR structures was identified. The RMSD between this
and the NMR structures ranged between 14 and 21 A˚.
(c) This structure underwent a MD simulation in water solution
in the presence of counter ions. It was inserted into a box of
,15, 000 water molecules of ,8061006100 A˚3 edges. The
overall charges of the system was neutralized by adding 9
Na+ ions. Periodic boundary conditions were applied, taking
care that the minimum distance between AS and its images
was larger than 12 A˚. The AMBER99 [51] force field was
used for the biomolecule and counter ions, and the TIP3P
[53] force field was used for water molecules. Electrostatic
interactions were calculated using the particle mesh Ewald
method with 64 grid points on each direction and Ewald
coefficient of 0.312. A cutoff distance of 10 A˚ for the real
part of the electrostatic and van der Waals interactions was
used. The time-step was set to 2 fs. The SHAKE algorithm
[54] was applied to fix all bond lengths. The simulations
were performed at T = 300 K and P = 1,013 bar by coupling
the systems with a Langevin thermostat [52] with a coupling
coefficient of 5 ps21, and a Nose-Hoover Langevin barostat
[55], with an oscillation period of 200 fs and the damping
timescale of 100 fs. The pressure coupling allowed the
system to reach a water density of about 0.98 g/cc. Three ns
of MD simulation were carried out. The final AS
conformation at the end of the MD simulation turned out
to be structurally different from the NMR structures: the
RMSD ranged again approximately between 14 and 21 A˚.
(d) Our AS structural model, relaxed in aqueous solution, was
selected as a novel, MD-derived conformation of AS for the
docking simulations. The seven ligands of Figure 1 were
docked into this final MD-derived structure as described in
the previous section. Thus, an additional 7 seven complexes
were considered and an additional 700 docking simulations
were performed (7 ligands6100 docking simulations).
MD of ASNdopamine complexes in aqueous solution. The
MD simulations of the ASNdopamine NMR-based complexes as
well as those of our theoretical models of the complexes were
carried out exactly as described above and for a 6 ns time-scale;
the only differences being (i) the presence of the ligands and (ii) the
number of counter ions (in the case where the ligand was DOP-H
the number of ions was 8). For the parameterization, the RESP
atomic charges [56] for each ligand were calculated at the HF/6-
31G* level of theory, using the GAUSSIAN98 suite of programs
[57] (Table S1). The atom types and parameters (i.e. van der
Waals, bond lengths, valence angles and dihedral angles) were
assigned according to the AMBER99 force field building
procedure [48]. The RMSDs and radii of gyration were
calculated as described by McLachlan and Allen MP et al.
[58,59]. The Tanimoto coefficients for the electrostatic potential
(Te) and shape (Ts) of the ligands [60] were calculated using the
EON code for chemical similarity analysis [61]. All the MD
simulations were performed using the NAMD program [62] and
the obtained results were analyzed using Gromacs [63] and VMD
programs [64].
The electrostatic interaction energies between residues of the
NAC region and the ligands were calculated using two approaches
which use the RESP atomic charges [56]. The first is a simple
point charge (PC) model in vacuo, assuming a dielectric constant of
AS/DOP Interactions
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1 (see Guidoni et al. [65]). The second is a finite-difference method
(Poisson-Boltzmann). For this, the APBS program [66] was used.
The temperature was set to 298K. The solvent and protein
dielectric constants were set to 78 and to 2, respectively. The
SASA-based apolar coefficient [67] (surface tension) was set to
0.105 kJ/mol/A˚ and the ionic strength to 0.1.
In both methods, all charges other than the ligands atoms and
the atoms in the specific residue in the NAC region were turned
off. The electrostatic interaction energies were calculated during
the dynamics at every 60 ps. We considered only the residues
which were found within 12 A˚ from the ligands (the distance is
measured between the center of mass of each residue in the NAC
region and the center of mass of the ligands) for at least 80% of the
dynamics. The averages values were then calculated. These
methodologies were used here only to provide qualitative results.
In vitro experiments
Cloning, expression and purification of a-synuclein and
its mutants. Human wild-type (WT) AS cDNA was cloned into
the bacterial expression vector pET-11a at the NdeI site. The
mutants were generated using site-directed mutagenesis employing
mutagenic primers and two-steps PCR. All constructs were
confirmed by DNA sequencing. E. coli BL21 cells were
transformed with the WT and mutant AS constructs. One
bacterial colony was inoculated into 5 ml SOC broth containing
70 mg/ml ampicillin (Q-Biogene, Serva) and incubated overnight
at 37uC with continuous shaking. Overexpression of the protein
was achieved by transferring 2.5 ml of the pre-culture to 500 ml
LB medium supplemented with 70 mg/ml ampicillin. The cells
were grown at 37uC, with continuous shaking to an OD at 600 nm
of about 0.4–0.6 followed by induction with 1 mM isopropyl-b-
thiogalactopyranoside (IPTG) for 3 hrs. After induction, the cells
were harvested by centrifugation at 5000 g for 10 min and stored
at 220uC. The cell pellet was re-dissolved in 50 mM Tris
(Applichem), 50 mM KCl (Applichem), 5 mM MgAc (Applichem),
0.1% Sodium Azide (Applichem), pH 8.5 (1 ml buffer/200 mg
pellet). The cell suspension was sonicated for 10 minutes, and the
lysate was centrifuged at 8000 g for 30 min. The supernatant was
separated from the pellet and the former was first boiled for
20 min, then centrifuged at 8000 g for 30 min, and finally filtered
through a 0.22 m filter (Millipore). The protein was firstly purified
through anion exchange chromatography (HiPrep Q FF column,
Amersham) in 20 mM Tris, pH 8.0/ 20 mM Tris, 1 M NaCl,
pH 8.0 followed by injection onto a size exclusion
chromatography column (Superdex 200 10/300 or Superdex
200 16/60, Amersham) in 50 mM Tris/HCl, pH 7.5. Purified
preparations were dialyzed against water for approximately
24 hrs, then lyophilized and stored at 220uC until use.
Fibrillization studies of WT and mutant a-synuclein. To
characterize the aggregation properties of WT and mutant AS,
proteins were dissolved in 20 mM Tris (Aldrich)/150 mM sodium
chloride (Aldrich) pH 7.4, at a concentration of 100 mM. The
concentration of AS was determined using its molar extinction
coefficient at 280 nm (i.e. e280 = 5120) on a Cary 100 Bio
spectrophotometer. The purified proteins were then subjected to
fibrillization conditions in absence or presence of an equimolar
quantity of dopamine hydrochloride (Fluka) at 37 uC with
continuous shaking for the indicated time points.
Thioflavin-T (ThT) assay. Fibril formation was monitored
by the ThT assay, which was performed by combining 10 ml of
aggregated AS with 80 ml Glycine-NaOH (Fluka) pH 8.5, and
10 ml of 100 mM Thioflavin-T (Sigma) in water. Fluorescence
measurements were recorded in an Analyst Fluorescence
instrument (LJL Biosystems). The excitation and emission
wavelengths were set at 450 nm and 485 nm, respectively. The
relative fluorescence at 485 nm was used as a measure of the
amount of fibrillar aggregates formed in solution.
Circular Dichroism (CD). The average secondary structure
of WT and mutant AS was determined by CD spectroscopy using
a Jasco J-815 Spectrometer (Omnilab). The Far UV-CD spectra
(195–250 nm, integration time of 2 seconds for 0.2 nm) were
collected at RT in a 1 mm path length quartz cuvette containing a
1:5 dilution in water of the samples (WT or mutant AS,
concentration 100 mM at time 0) subjected to assembly
conditions (72 hrs at 37uC with shaking) in absence or presence
of 100 mM DOP.
Gel Electrophoresis (SDS-PAGE). The AS samples were
filtered through 0.22 mm PVDF filters, diluted in loading buffer
[4% (w/v) Sodium dodecyl sulphate (Fluka), 60 mM Tris, pH 6.8,
10% (v/v) Glycerol (Fluka), 5% (v/v) b-mercaptoethanol (Fluka),
8% (w/v) bromophenol blue, 45.8% (v/v) distilled water] and
separated on 12% SDS [(31.3% (v/v) Acrylamide N-N9-
methylenebisacrylamide 37,5:1 solution (Fluka), 25% (v/v) 1.5 M
Tris, pH 8.8 (Sigma), with 0.4% (v/v) SDS (Sigma), 42.7% (v/v)
distilled water, 0.3% (v/v) ammonium persulfate (APS) and 0.12%
(v/v) N,N,N9,N9-tetramethylenediamine, (TEMED)], 1 mm gel.
Gels were stained with Simply Blue safe stain (Invitrogen)
according to manufacturer’s instructions.
Transmission Electron Microscopy (TEM). For EM
studies WT and mutant AS samples (35 mM) were deposited on
Formvar-coated 200 mesh copper grids (Electron Microscopy
Sciences). Grids were washed with two drops of water and stained
with two drops of freshly prepared 0.75% (w/v) uranyl acetate
(Electron microscopy sciences). Specimens were inspected on a
Philip CIME 12 electron microscope, operated at 80 kV. Digitized
photographs were recorded with a slow scan CCD camera (Gatan,
Model 679).
Results
DopamineNAS structural models
A set of 6 structures representing about 75% of the total number
of conformers was selected from the NMR ensemble of ,3000
structures using a cluster methodology (see Materials and
Methods). The adducts with dopamine (DOP) and its derivatives
(Figure 1) were constructed by molecular docking (4,200
complexes). The ligands, which were allowed to be flexible, were
docked onto the entire protein (considered rigid) and then, for
individual conformations with each ligand, the adduct with the
ligand in the most probable region of interaction was selected for
subsequent analysis (see Materials and Methods for details). Due to
the limitations of this procedure for an unstructured protein [68],
these calculations are meant only to build up initial structural
models for the subsequent MD simulations. Crosschecks were
made to ensure that the choice of the initial structure is not critical
for the results (see next Section). The ligands’ positions turned out
to be rather spread along the protein (Table S2 and Figure S2).
In the MD simulations of the resulting 42 adducts in aqueous
solution, the ligands formed stable contacts with AS in 60% of the
cases (Table S3). We refer to these as ‘stable’ adducts. Their
RMSD and radius of gyrations (Rg) appeared to fluctuate around
an average value after 3 ns, albeit with rather large values (Table
S4). This suggested that the complexes are reasonably equilibrated
in spite of the large conformational flexibility.
In as much as 73% of the ensemble of the stable adducts, the
binding region included the 125YEMPS129 residues in the C-
terminal region (Figure 2A and Table 1); specifically, it involved
hydrophobic interactions between the aromatic ring of the ligand
AS/DOP Interactions
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and hydrophobic side chains of AS (Table 1 shows the interactions
and additional information is presented in Table S5 and Figures
S3–S4). In addition, the O and N groups of the ligands formed, in
some cases, hydrogen bonds (H-bonds) with polar groups in the
same region of AS. The similar binding mode is paralleled by the
remarkable structural and electrostatic similarity between the
ligands, which is pointed out by the calculated Tanimoto
coefficients for the electrostatic potential (Te) and shape (Ts)
[60] between each of them (values ranging between 0.760.3 and
0.860.1 for Te and Ts, respectively, see Table S6). In conclusion,
the ligands shared similar binding modes in which the most
frequent contacts involve the ligands’ aromatic ring moieties.
A visual inspection of MD snapshots suggested that the C-
terminal binding region assumes a relatively ordered conformation
upon binding of the ligands (Figure 2B). We quantified this
property by calculating the root mean square fluctuations
(RMSF’s) and the standard deviation (SD’s) of the angles involving
Ca carbon atoms. We found it convenient, in particular, to focus
on the n, n+1, n+4 angles. In all of the stable complexes, (i) the
RSMF’s of the C-terminal residues are smaller than those of the
N-terminal residues (Figure S5); (ii) the smallest values of the SD’s
of the angles (n, n+1, n+4) were those of the C-terminal binding
region: the SD of the angle 125-126-129 being 13u; compared with
the value of 28u averaged over all the other angles (Figure 2B) and
with those of the correspondent angles in the unstable complexes
(average 29u, Figure 2B). For the rest of the protein, we noticed
that the ligands spent a significant amount of the simulated time in
proximity to the NAC residues (Figure S6), although they never
formed a direct contact with them. According to electrostatic
calculations based on a simple point charge model, E83 within the
NAC region contributed the most to the long-range electrostatic
stabilization of the ligands (at least 30% larger than any other
residue in the region, Figure S6). Poisson-Boltzmann calculations
provided qualitatively the same results, namely that E83 is the
residue in the NAC region forming the largest electrostatic
interactions with the ligand (Figure S6) (we further notice that the
point charge model provides larger values than those obtained for
Poisson-Boltzmann calculations; one has to keep in mind that
these calculations are very approximate and cannot be used for
quantitative predictions). Test calculations suggested that nullify-
ing E83 charge results in a large decrease of such interactions
(,60%). Within the limitations of our simple analysis, which is
used here only for qualitative comparisons, we suggest that
additional stabilization of dopamine in its adducts with AS may
arise from electrostatic interactions with E83.
In all the remaining simulations, the ligands did not bind in a
stable manner with the protein (Table S3) and the structures
appeared not to be equilibrated in the timescale investigated. For
example, in one case the DOP ligand moved from its starting
binding region (residues 92, 93 and 103) towards residues 99, 105
and 106 after 3 ns, and did not form stable interactions with the
protein during the time scale of the MD simulation (animation
available at http://people.sissa.it/,herrera/AS/animations). This
was also the case for unbound protein, preventing comparisons
between this and the ‘stable’ complex.
Crosscheck of our results
Although our conformers are representative of most of the AS
structural ensemble emerging from NMR, our results may be
dependent on the fact that we use a large, but certainly not
exhaustive, ensemble of adducts. In this section, we address this
issue by performing two additional calculations, as described in the
Materials and Methods section.
(i) We tested whether starting from a very different structure
from those based on NMR would yield similar results. To
obtain such a structure, we performed MD calculations
without any input from experimental data. We selected a
Figure 2. Molecular dynamics simulations. (A) The six most representative conformations of AS, as obtained by the cluster procedure (see
Material and Methods) in complex with some of the ligands (in red color). The picture has been obtained after 6 ns MD simulations. In all
circumstances, the 125–129 residues (blue licorice) are in contact with the ligands (all the resulting complexes are shown in Figure S3). (B) The 125-
126-129 Ca angles show the smaller spread around its average value on all the stable complexes. Top. Conformation of the C-terminal region in the
stable and unstable adducts. Middle: Average values of angles formed by Ca (n2n+12n+4) on stable (left) and unstable (right) adducts. Bottom:
standard deviation of those angles (the average is 28u for the stable adducts and 29u for the unstable adducts).
doi:10.1371/journal.pone.0003394.g002
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Table 1. H-bond and hydrophobic contacts in DopamineNAS ‘stable’ adducts.
Hydrogen Bonds Hydrophobic contacts
Repr. Cluster 1 (39%) DCH Met127(O)-DCH(N1), (D: 3.760.8 A˚) Tyr125, (D: 4.760.6 A˚)
Ser129(O)-DCH(O1), (D: 4.260.5 A˚) Tyr136, (D: 6.460.6 A˚)
DHI Glu137(OE2)-DHI(N1), (D: 2.860.2 A˚) Lys80, (D: 4.060.3 A˚)
Asp135, (D: 7.060.3 A˚)
Tyr136, (D: 9.960.5 A˚)
DOP Lys96, (D: 6.260.7 A˚)
Val118, (D: 6.0609 A˚)
Pro120, (D: 5.460.5 A˚)
DOP-H Glu123(OE2)-DOP-H(O1), (D: 3.561.2 A˚)
Glu123(OE2)-DOP-H(O2), (D: 3.060.6 A˚)
DQ Asp135(N)-DQ(O2), (D: 3.360.4 A˚) Ile112, (D: 6.660.7 A˚)
Gly111(O)-DQ(N1), (D: 3.961.0 A˚) Asp135, (D: 5.461.0 A˚)
IQ Thr81, (D: 4.060.2 A˚)
LEUK Glu131, (D: 7.462.2 A˚)
Gly132, (D: 5.862.1 A˚)
Repr. Cluster 2 (15%) DOP-H Ser129(O)-DOP-H(N1), (D: 3.760.9 A˚) Ser129, (D: 5.460.7 A˚)
Glu131(O)-DOP-H(N1), (D: 2.860.2 A˚)
Repr. Cluster 3 (7%) DOP Met127, (D: 7.862.4 A˚)
DQ Thr81(N)-DQ(O2), (D: 4.660.5 A˚) Lys34, (D: 6.960.7 A˚)
IQ Lys34, (D: 5.960.8 A˚)
Repr. Cluster 4 (6%) DCH Ala90(N)-DCH(O1), (D: 3.360.7 A˚) Phe94, (D: 4.560.3 A˚)
Lys97(NZ)-DCH(O2), (D: 3.060.5 A˚) Val118, (D: 5.760.6 A˚)
Tyr136 (D: 6.360.5 A˚)
DHI Ala90, (D: 4.860.3 A˚)
Phe94, (D: 6.560.5 A˚)
Lys97, (D: 4.960.3 A˚)
DOP Gly68(N)-DOP(O1), (D: 3.460.4 A˚) Gly67, (D: 4.860.6 A˚)
His50, (D: 5.060.5 A˚)
Val66, (D: 6.260.5 A˚)
DOP-H Thr92(O)-DOP-H(N1), (D: 3.560.8 A˚) Tyr125, (D: 5.560.7 A˚)
DQ Gln134(NE2)-DQ(O2), (D: 3.560.5 A˚) Tyr39, (D: 4.760.3 A˚)
Val49, (D: 6.360.5 A˚)
IQ Glu123(OE2)-IQ(N1), (D: 3.260.8 A˚) Phe94, (D: 5.460.6 A˚)
Met116, (D: 5.560.7 A˚)
Repr. Cluster 5 (4%) DCH Glu105(OE2)-DCH(N1), (D: 4.060.7 A˚) Asp115, (D: 4.860.4 A˚)
Met116(O)-DCH(N1), (D: 3.560.4 A˚) Pro117, (D: 6.660.5 A˚)
DOP-H Glu105(OE2)-DOP-H(O1), (D: 2.560.1 A˚) Val118, (D: 6.060.6 A˚)
IQ Tyr125, (D: 6.261.9 A˚)
Repr. Cluster 6 (4%) DCH Ser129, (D: 6.361.2 A˚)
Tyr133, (D: 5.761.4 A˚)
DHI Gly41, (D: 6.460.8 A˚)
Pro128, (D: 4.860.6 A˚)
DOP Ala89(O)-DOP(O1), (D: 3.560.9 A˚) Leu113, (D: 6.060.7 A˚)
Asp135, (D: 6.360.4 A˚)
DOP-H Asp98(OD1)-DOP-H(N1), (D: 2.960.4 A˚) Asn65, (D: 5.460.6 A˚)
Glu61, (D: 5.560.2 A˚)
DQ Ala89(O)-DQ(N1), (D: 3.360.5 A˚) Ala90, (D: 5.860.5 A˚)
Ser129, (D: 6.361.4 A˚)
Tyr133, (D: 6.161.3 A˚)
IQ Ala56, (D: 5.561.0 A˚)
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model with the largest RMSD relative to the NMR structure
(see Materials and Methods for details). Docking the ligands
to this structure provided highly different models from those
obtained starting from the NMR structures (RMSD ranging
from 14 to 20 A˚). However, the ligands did bind again to the
C-terminal region, in a manner similar to how they did to the
NMR structures (see Table 1 and Table S5). Moreover, they
were stabilized, also in this case, by electrostatic interactions
with E83 (Figure S6). The RMSD and the Rg fluctuated also
in this case around an average value after 3 ns (Table S4).
Thus, also in these models, the ligands do interact close to the
C-terminal region (including residues 125YEMPS129) and
they form long-range electrostatic interactions with E83,
which is consistent with what we observed using structures
based on NMR studies.
We notice that the theoretical adducts are not representatives
of the entire ensemble of structures that could be obtained by
MD simulations. In particularly, they will be different if we
change the initial structure and/or the simulation time
length. However, our goal here is to use molecular dynamics
to provide one additional structure which is largely different
from those obtained by NMR representatives, rather than
providing an additional ensemble of theoretically built (and
therefore less reliable) models. The MD simulations are
therefore used here to test whether the results obtained using
the NMR representative structures can be obtained using
dramatically different structures derived from MD simula-
tions.
(ii) Next, we repeated the entire computational procedure on the
NMR structure using a different clustering algorithm [47] on
a different number of initial conformers (1,000 conformers
randomly chosen among the 3,062 initial ones). For this
cluster analysis, a set of 18 representative conformations
representing about 50% of the total number of chosen
conformers were selected (see the supplementary informa-
tion: ‘‘Cluster analysis S2’’). The ligands were docked onto
the representative conformations as in the previous analysis.
The MD simulations of the ASNligands complexes were also
carried out as previously described. The results of these
simulations showed that also for these conformations, the
ligands bound mostly to the C-terminal region (Figures S7,
S8 and S9 and Tables S7–S8) which assumed a relatively
ordered conformation upon binding of the ligands (Figure
S10). The complexes also reveal an additional electrostatic
stabilization mediated by the interactions between the ligands
and Glu83 in the NAC region (Figure S11).
These results demonstrate that our model for AS-dopamine
interactions is robust and does not depend significantly on the
chosen clustering analysis and/or the chosen number of NMR
conformations.
We conclude that, no matter from which structure we start
from, the ligands bind mostly to the C-terminal part of the protein
which includes the 125YEMPS129 region. This result is consistent
with the experimental observation that dopamine binds in vitro to
this region [38,40]. In spite of the limitations of the method used
here to investigate dopamine binding to AS (especially the
timescale and the large, yet surely not exhaustive ensemble of
structures investigated here) the ligands appear to recognize the C-
terminal region rather independently from its initial conformation.
A possible explanation for this fact is offered by the observation
that this region contains as many as five proline residues (in
contrast to the rest of the protein, which does not contains
prolines). In fact, this can impose local restrictions stabilizing the
structure of the backbone of this region as it was shown for another
member of AS family, b-synuclein, which shares 60% of sequence
identity and contains 8 prolines in its C-terminal region [69].
Testing the structural predictions by in vitro fibrillization
studies
On the basis of the above results, we conclude that the ligands
form nonspecific hydrophobic interactions with all of the five
residues in the 125YEMPS129 region (Table 1) and form H-bond to
E126 and S129 in some cases. In all cases, AS always assumes a
similar, kinked conformation in its binding region (Figure 2B). In
addition, the ligands may be significantly stabilized by electrostatic
interactions with E83. To test the validity of these conclusions,
obtained within the limitation of the computational protocol
outlined above, we investigated in vitro the aggregation properties
in the presence and absence of dopamine of four alanine mutants
of AS, which involve the 125YEMPS129 residues in the C-terminal
region, as well as E83 in the NAC region (Table 1): E83A, E126A,
S129A and E83A/E126A/S19A. Because our calculations suggest
that ligand-AS interactions at the C-terminus are dominated by
nonspecific hydrophobic interactions, we predict that the E126A
and S129A mutations should not significantly alter the ligand-AS
interaction. In addition, in the case of S129A, the Ser to Ala
mutation might not affect H-bonding with the ligand as it involves
Table 1. cont.
Hydrogen Bonds Hydrophobic contacts
Glu57, (D: 5.560.9 A˚
MD Derived DCH Ala90, (D: 6.761.8 A˚)
DHI Glu83, (D: 12.161.5 A˚)
Ile88, (D: 5.160.5 A˚)
DOP Glu131(OE2)-DOP(O1), (D: 3.760.9 A˚) Gln134, (D: 8.461.5 A˚)
DOP-H Glu110(OE2)-DOPH(O1), (D: 2.660.4 A˚) Gly111, (D: 4.961.8 A˚)
Glu114(OE2)-DOPH(N1), (D: 2.960.5 A˚)
DQ Asn122(ND2)-DQ(O1), (D: 3.960.8 A˚) Asp121, (D: 6.561.1 A˚)
Several of then shown interactions with the C-terminal region, including the 125YEMPS129 region.
The distance (D) in the hydrogen bond column was measured between the heavy atoms. The hydrophobic contacts were measured as the distance (D) between the
center of mass of the ligand and the specific amino acid.
doi:10.1371/journal.pone.0003394.t001
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the backbone. In contrast, the E83A mutation is expected to affect
dopamine affinity for AS (and therefore it might affect the
fibrillization process).
Recombinant human WT, E83A, E126A, S129A and E83A/
E126A/S129A AS proteins were expressed and purified as
described in the ‘‘Materials and Methods’’ section. The aggrega-
tion properties of the five proteins were determined by incubating
100 mM of protein in TRIS buffer (20 mM Tris, 150 mM NaCl,
total volume = 500 ml in 1.5 ml plastic tubes) at 37 uC with
continuous shaking for 72 hrs in the absence or presence of
equimolar dopamine. At regular intervals, aliquots were removed
and subjected to analysis by ThT fluorescence assay, SDS-PAGE
gel, circular dichroism (CD) and electron microscopy (EM). All the
mutants showed increased aggregation relative to the WT
(Figure 3A). Interestingly, the two AS variants containing the
E83A mutation retained the ability to form fibrils in the presence
of an equimolar quantity of dopamine (Figure 3A) whereas fibril
formation by the WT, E126A and S129A variants was abolished
in the presence of dopamine. This result clearly suggests that the
nature of dopamineNAS interactions in the C-terminal region is
distinct from that of the interactions in the NAC region, consistent
with our predictions. A consistent picture was obtained by
monitoring the loss of soluble (monomers, oligomers and
protofibrils) protein during the fibrillization reaction by SDS-
PAGE. Aliquots of the samples at various time points were diluted
in buffer (factor 1:10) and filtered through 0.22 mm PVDF filters to
eliminate fibrillar and insoluble aggregates, before analysis in 12%
PAA gels with Coomassie Blue staining. The signal corresponding
to the protein in the flow-through (monomer and soluble
oligomers) was quantified using the software ImageJ. In agreement
with the ThT data, we saw a decrease of soluble content that was
proportional to the degree of aggregation of each protein
(Figure 3B). In the presence of dopamine, the majority of WT,
S129A, and E126A protein remained in solution, whereas very
little soluble protein remained in the case of the two E83A-
containing mutants (Figure 3B, red rectangles).
The CD spectra showed that all proteins adopt predominantly
random coil conformation in solution (data not shown) but form b-
sheet rich structures after incubation for 72 hrs at 37uC. In the
absence of dopamine and after incubation for 72 hrs, the majority
of WT, E126A, and S129A precipitated out of solution and the
CD spectra of the remaining material exhibited a predominantly
random coil structure, except for S129A which exhibited a spectra
consistent with species (soluble aggregates) rich in b-sheet structure
(Figure 3C). Co-incubation with dopamine prevented the
transition from random coil to b-sheet in the case of WT,
S129A, E126A, but not in the case of E83A or E83A/E126A/
S129A, further confirming that dopamine is able to prevent the
fibrillization of the WT, E126A and S129A mutants but not of the
E83A and E83A/E126A/S129A mutants (Figure 3C).
To characterize the extent of aggregation and the effect of
dopamine on the structural properties of the AS aggregates, we
performed EM studies on AS samples incubated for 72 hrs in the
presence or absence of dopamine. In the absence of dopamine,
after 48–72 hrs the mutant proteins showed abundant fibrils
resembling those formed by WT AS (Figure 4, left panels). In the
presence of dopamine, WT, E126A and S129A formed predom-
inantly soluble aggregates and no mature fibrils could be detected
in these samples, which is consistent with previously reported data
on the WT protein. On the contrary, addition of dopamine did not
inhibit fibril formation or change the structure of the fibrils formed
by both E83A containing mutants (Figure 4, right panels).
Discussion
We have presented both molecular dynamics and in vitro
biophysical investigations of complexes formed by AS and
dopamine and several of its derivatives in aqueous solution. These
calculations, which were based on structures representing about
75% of the conformations obtained by NMR spectroscopy [22],
suggest that the ligands bind non-covalently to the C-terminal
region including the residues 125YEMPS129. This result is
consistent with data obtained by in vitro fibrillization studies
[38,40] and the proposed role of the C-terminal region
encompassing these residues in inhibiting the aggregation of AS.
In all the cases that we investigated, the dopamine-binding region
assumed a similar structure (Figure 2B). Moreover, the same
results were obtained by applying our computational protocol to
theoretical models based on MD simulations of AS in aqueous
solution as well as by performing a rather different clustering
analysis on the NMR structures. We therefore suggest that, in spite
of the limitations of the computational methodology presented,
our calculations provide a consistent picture for the structural
determinants of the binding region for the non-covalent
complexes: the fingerprint of dopamineNAS non-covalent com-
plexes is the formation of nonspecific hydrophobic contacts
between the ligands’ aromatic ring and the 125YEMPS129 region
in the C-terminus (Table 1), which is aided by the particular
conformation adopted by the binding region to accommodate the
ligand (Figure 2B). These interactions are also complemented by
nonspecific H-bonding interactions. In addition, dopamine and its
derivatives are stabilized by significant electrostatic interactions
with E83 in the NAC region (Figure S6).
Thus, based on our computational findings, we hypothesized
that the 125YEMPS129-DOP, nonspecific hydrophobic interactions
may affect the AS-DOP binding and hence DOP’s ability to
modulate AS fibrillization. In addition, replacement of E83 with
alanine in the NAC region should abolish the favorable long range
electrostatic interactions with the ligands upon binding to the C-
terminal region. To test this hypothesis, we mutated selected
residues involved in dopamine interactions and investigated the in
vitro aggregation properties of these mutants (E83A, E126A,
S129A and the triple mutant E83A/S129A/E126A) using an
array of biophysical methods.
Our calculations suggest that hydrophobic interactions with the
125YEMPS129 C-terminal region play a critical role in the
interaction of AS with DOP and its derivatives. We found that
single amino acid substitutions (E126A and S129A) in this region
do not abolish DOP inhibition of AS fibrillization in vitro. Indeed,
previous studies have shown that abolishment of DOP inhibition
of AS aggregation requires substitution of all the 5 amino acids in
the 125YEMPS129 region (YEMPS to FAAFA) or deletion of amino
acids 125–140 [38,40].
These results suggest, in agreement with our calculations
showing nonspecific hydrophobic interactions between the aro-
matic ring of the ligand and hydrophobic side chains of the C-
terminus, that the entire region is important for DOP binding.
Interestingly, the E83A mutation in the NAC region strongly
impairs the ability of dopamine to inhibit AS aggregation. This
mutation may either prevent DOP binding to 125YEMPS129,
which is consistent with our conclusion that dopamine affinity is
stabilized by E83 long range electrostatic interactions, or alter
some property of the NAC region, which is required for DOP
inhibition of AS fibrillization. Therefore, our findings suggest that
both the C-terminus and the NAC region are important for the
inhibition of AS fibrillization by DOP.
AS/DOP Interactions
PLoS ONE | www.plosone.org 8 October 2008 | Volume 3 | Issue 10 | e3394
Figure 3. In vitro fibrillization of a-synuclein. (A) Kinetics of fibrillization of WT and mutant (E83A, E126A, S129A and Triple) a-synuclein under
assembly conditions in absence or presence of an equimolar quantity of dopamine (DOP) as monitored by the enhancement in Thioflavin-T (ThT)
fluorescence intensity over time. Data are expressed as the mean6SEM (Standard Error of the Mean) of 2 or 3 independent experiments. (B) Amount
of soluble WT and mutant a-synuclein protein remaining in solution after 72 hrs incubation under assembly conditions in absence or presence of an
equimolar quantity of DOP monitored by SDS-PAGE. (C) CD spectra of the soluble WT and mutant a-synuclein proteins remaining in solution after
72 hrs incubation under assembly conditions in absence (blue line) or presence (red line) of an equimolar quantity of DOP.
doi:10.1371/journal.pone.0003394.g003
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The protocol that we have adopted here, which combines in
silico and in vitro methods, may help devise novel ligands that mimic
interactions between dopamine and AS. These molecules may act
as potential inhibitors of AS aggregation and provide initial lead
structure in developing small molecule therapeutics for PD and
related synucleinopathies. In order to explore these opportunities,
however, further studies will need to establish whether DOP
inhibition of AS aggregation is toxic or protective in neurodegen-
eration. Further, this type of approach may be extended to other
disease-related naturally unfolded proteins.
Supporting Information
Figure S1 Structural models: A. Clustering of the 3,062 NMR
structure selected from NMR experiments: Histogram of the RMSD
pair distance matrix. B. MD simulation: Cartoon of the AS
conformation obtained by setting the backbone dihedral angles Q,
y= 180u of all residues except proline and Q=260u, y= 180u for
proline. This structure was used for the MD simulations in implicit
solvent. For the sake of clarity, only the backbone atoms are shown.
Found at: doi:10.1371/journal.pone.0003394.s001 (0.20 MB TIF)
Figure S2 Molecular docking: Results for the 100 runs for each
of the 6 AS representatives conformations with DCH (yellow),
DHI (pink), DOP (light blue), DOP-H (blue), DQ (green), IQ (red)
and LEUK (black) (54 complexes). Clustering of the doking results,
as implemented in AUTODOCK, plotted as a function of the
AUTODOCK scoring function (in Kcal/mol). Inset: The number
of hits (defined in Table S2) between AS and the respective ligand.
Found at: doi:10.1371/journal.pone.0003394.s002 (0.60 MB PDF)
Figure S3 MD simulations of the ‘‘stable’’ DOP/AS complexes.
Structures and Ca contacts maps for the last MD snapshots. In the
structures, residues 125–129 and E83 are colored in red and blue,
respectively. In the contact maps, the x and y axis indicate the
residues number in the AS sequence. The contact maps were
calculated based on the Ca-Ca distance (a graph square is colored
black at 0.0 A distance, to a linear gray scale between 0.0 and 10.0
A, and white when equal to or greater than 10.0 A).
Found at: doi:10.1371/journal.pone.0003394.s003 (0.81 MB PDF)
Figure S4 MD simulations of the stable complexes. Ligand/
protein interactions are represented using Ligplot program.
Found at: doi:10.1371/journal.pone.0003394.s004 (0.92 MB
DOC)
Figure S5 Structural fluctuations. Molecular dynamics of the
NMR-derived conformations with the ligands. The Root mean
square fluctuations (RMSF’s, in A) are reported for the 26 stable
complexes.
Found at: doi:10.1371/journal.pone.0003394.s005 (0.04 MB PDF)
Figure S6 Electrostatic interactions: interactions energies be-
tween the ligands and residues in the NAC region, as obtained by
a simple point charge model and by Poisson-Boltzmann
calculations. These interactions are averaged along our molecular
dynamics of the e NMR derived and MD-derived ASNdopamine
adducts. Top: Number contacts (defined in Materials and
Methods) between NAC residues and the ligands. The residues
selected for the electrostatic analysis (see Materials and Methods)
Figure 4. TEM analysis: WT and mutant a-synuclein (E83A,
E126A, S129A and Triple) filament assembly in absence or
presence of an equimolar quantity of dopamine (DOP). Proteins
were incubated under assembly conditions for 72 hrs and analyzed by
negative staining EM as described in Materials and Methods.
doi:10.1371/journal.pone.0003394.g004
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are marked in black. Bottom. Averaged energies values for the
selected residues normalized to the largest values, as in the work of
Guidoni et al. For the point charge model and Poisson Boltzmann
calculations, Av =22.7 Kcal/mol and 20.3 Kcal/mol.
Found at: doi:10.1371/journal.pone.0003394.s006 (0.42 MB TIF)
Figure S7 Molecular docking and MD simulations of dopamine
and its derivatives onto AS: A) Number of hits (defined in Table
S2) between AS and DOP, DOP-H and DCH, as obtained by
5,400 docking runs. B) In 11 simulations out of 18, the ligands
bind to the 125YEMPS129 region. Here we show six of those
conformations where the 125–129 residues and E83 are colored in
blue, the ligand is colored in red.
Found at: doi:10.1371/journal.pone.0003394.s007 (1.39 MB TIF)
Figure S8 MD simulations of the stable DOP-, DOP-H- and
DCH-AS complexes. Final structures and contact maps for the last
MD snapshots. Black to white scale as in Figure S3. Residues 125–
129 and Glu 83 are colored in blue and the ligands are colored in
red.
Found at: doi:10.1371/journal.pone.0003394.s008 (0.39 MB
DOC)
Figure S9 MD simulations in the ‘‘stable’’ complexes from the
second cluster analysis. The ligands and the residues involved in
the interactions are shown in sticks. Hydrogen bonding and
hydrophobic interactions are shown as dashed lines. Snapshots
taken from the last frame of the MD simulations.
Found at: doi:10.1371/journal.pone.0003394.s009 (0.26 MB PDF)
Figure S10 MD simulations of the NMR-derived conformations
from the second cluster analysis. Top: Average values of angles
formed by Ca (n2n+12n+4) on stable (left) and unstable (right)
adducts. Bottom: standard deviation of those angles (the average is
30u for the stable adducts and 28u for the unstable adducts).
Found at: doi:10.1371/journal.pone.0003394.s010 (5.49 MB TIF)
Figure S11 MD simulations of the NMR-derived conformations
from the second cluster analysis.: Ligand/NAC interactions.
Left:Number of times that NAC aminoacids are found within a
12 A from the ligands of Figure 1.The residues selected for the
electrostatic analysis are marked in black. Right. Averaged
energies values (calculated using a point charge model), for the
selected residues (Res), normalized to the largest value. The
average interaction is 21.4 Kcal/mol.
Found at: doi:10.1371/journal.pone.0003394.s011 (0.23 MB TIF)
Table S1 MD simulations. Atoms labeling and RESP atomic
charges of the ligands in Figure 1.
Found at: doi:10.1371/journal.pone.0003394.s012 (0.12 MB
DOC)
Table S2 Molecular Docking: Top) Number of hits between a-
synuclein (AS) and the seven ligands as obtained by 4,200 docking
runs of Autodock. The hits are defined here when the distance
between at least one AS’s Ca atom and the ligands’ center of mass
is lower than 5 A. Bottom) Relative contribution for the binding of
the C-terminal regions, calculated as percentages of the total
number of ligand-protein contacts
Found at: doi:10.1371/journal.pone.0003394.s013 (0.11 MB
DOC)
Table S3 Stabilities. The stabilities of the local interactions
between the ligand and AS for all MD simulations are reported here.
Found at: doi:10.1371/journal.pone.0003394.s014 (0.03 MB
DOC)
Table S4 MD simulations. RMSD (A) and radius of gyration (A)
of the so-called ‘stable’ adducts.
Found at: doi:10.1371/journal.pone.0003394.s015 (0.08 MB
DOC)
Table S5 MD simulations of dopamine and its derivatives in
complex with AS (49 complexes). Distance between the center of
mass of dopamine (and its derivatives reported in Figure 1) and
that of residues E83, 110–140. The average values (Av.), along
with their standard deviations (SD), are reported.
Found at: doi:10.1371/journal.pone.0003394.s016 (0.57 MB
DOC)
Table S6 Structural and electrostatic similarity across the
ligands reported Figure 1. The Tanimoto coefficients character-
izing the shape (Ts) and the electrostatic potential (Te) of the
ligands reported in Figure 1 are presented. DOP-H is not shown
because it is charged, unlike all of the other ligands.
Found at: doi:10.1371/journal.pone.0003394.s017 (0.04 MB
DOC)
Table S7 MD simulations of NMR-derived conformations from
the cluster analysis of Kelley et al. Hydrogen bonds and
hydrophobic contacts for 11 out of the 18 analyzed complexes
forming interactions with the protein. Several of then shown
interactions with the C-terminal region, including the
125YEMPS129 region. The distance (D) in the hydrogen bond
column was measured between the heavy atoms. The hydrophobic
contacts were measured as the distance (D) between the center of
mass of the ligand and the specific amino acid.
Found at: doi:10.1371/journal.pone.0003394.s018 (0.04 MB
DOC)
Table S8 MD simulations of the dopamine forms/AS adducts.
The average values (Av.) with their standard deviations (SD) of the
distance between the center of mass of E83 along with the C-
Terminal residues (from 110 to 140) and dopamine, along the
trajectory, are reported here.
Found at: doi:10.1371/journal.pone.0003394.s019 (0.25 MB
DOC)
Cluster Analysis S1 Cluster Analysis of Micheletti et al.
Found at: doi:10.1371/journal.pone.0003394.s020 (0.04 MB
DOC)
Cluster Analysis S2 Cluster analysis of Kelley et al.
Found at: doi:10.1371/journal.pone.0003394.s021 (0.04 MB
DOC)
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